We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biomarker Panel Predicts Severity of Pollen Allergy Symptoms

By LabMedica International staff writers
Posted on 12 May 2020
A team of German researchers has identified a panel of biomarkers that predicts the severity of allergic symptoms even before the start of the pollen season.

In addition to physical symptoms such as sneezing, rhinitis, and watery eyes pollen exposure induces local and systemic allergic immune responses in sensitized individuals. More...
The kinetics of symptom expression under natural pollen exposure have never been systematically studied, especially in subjects without allergy.

To rectify this situation, investigators at the Helmholtz Zentrum München - German Research Center for Environmental Health (Munich, Germany) compared humoral immune response kinetics in a panel study of subjects with seasonal allergic rhinitis (SAR) and subjects without allergy.

Subjects were monitored over a period of one year. In addition to a digital symptom diary kept daily by the study participants, the investigators analyzed samples of blood and nasal secretions. They then compared immune variables (cytokines, chemokines, and pollen-specific immunoglobulins) in samples obtained during and after the pollen season.

Results revealed that allergic symptoms appeared following exposure to concentrations of airborne pollen in subjects with SAR with a time lag between 0 and 13 days depending on the pollen type. Of the seven nonallergic subjects four also exhibited in-season symptoms whereas three did not. Cumulative symptoms in those without allergy were lower than in those with SAR but followed pollen exposure with similar kinetics. Principal component analysis and Spearman correlations identified nasal levels of IL-8, IL-33, and Betula verrucosa 1-specific IgG4 (sIgG4) and Betula verrucosa 1-specific IgE antibodies as predictive for seasonal symptom severity.

First author Mehmet Gökkaya, a researcher at the Helmholtz Zentrum München - German Research Center for Environmental Health, said, "The identification of biomarkers helps us in three ways. Firstly, by predicting the severity of nasal symptoms we can better identify the patients who benefit the most from therapeutic treatment. Secondly, biomarkers can help us understand the processes at work during the development of allergies in non-allergic patients and so help us to be ultimately able to prevent them. And thirdly, biomarkers can be used to identify the physiological processes that originally cause these symptoms. Possibly this could be a new starting point for the development of novel therapeutics."

The study was published in the April 6, 2020, online edition of the Journal of Allergy and Clinical Immunology.

Related Links:
Helmholtz Zentrum München - German Research Center for Environmental Health


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.